Comparative Pharmacology
Head-to-head clinical analysis: VIGABATRIN versus ZTALMY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIGABATRIN versus ZTALMY.
VIGABATRIN vs ZTALMY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversibly inhibits GABA transaminase, increasing brain GABA levels.
Ganaxolone is a positive allosteric modulator of GABAA receptors, acting at extrasynaptic and synaptic receptors to enhance chloride ion conductance and inhibit neuronal excitability.
Adults: 500 mg orally twice daily; may increase by 500 mg/day every 7 days up to 1500 mg twice daily. For refractory complex partial seizures, maximum 3000 mg/day.
Initial: 5 mg orally once daily for 7 days; titrate by 5 mg/day every 7 days to a maintenance dose of 30 mg once daily. Maximum: 30 mg daily.
None Documented
None Documented
5-8 hours in young adults; 12-17 hours in elderly; prolonged with renal impairment.
Clinical Note
moderateVigabatrin + Venlafaxine
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Venlafaxine."
Clinical Note
moderateVigabatrin + Nefazodone
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Nefazodone."
Clinical Note
moderateVigabatrin + Stiripentol
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Stiripentol."
Clinical Note
moderateVigabatrin + Clomipramine
Terminal elimination half-life is approximately 30 hours (range 20-40 hours) in adults, supporting once-daily dosing. Steady-state is achieved within 5-7 days.
Renal: ~80% unchanged in urine; fecal: <5%.
Primarily hepatic metabolism via glucuronidation and oxidation; <1% excreted unchanged in urine. Fecal elimination accounts for approximately 90% of the administered dose, with <5% in urine.
Category A/B
Category C
Anticonvulsant
Anticonvulsant
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Clomipramine."